Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $917.00 by Analysts at The Goldman Sachs Group

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lowered by The Goldman Sachs Group from $1,019.00 to $917.00 in a research note published on Monday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on the company. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Sanford C. Bernstein dropped their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Wells Fargo & Company decreased their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $964.88.

Regeneron Pharmaceuticals Stock Up 3.0 %

Shares of Regeneron Pharmaceuticals stock opened at $571.06 on Monday. The company has a 50-day simple moving average of $657.03 and a two-hundred day simple moving average of $749.93. Regeneron Pharmaceuticals has a 52-week low of $525.99 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market capitalization of $62.43 billion, a PE ratio of 14.92, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the business earned $11.86 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.62%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Capital International Investors lifted its holdings in Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares in the last quarter. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $802,036,000. GAMMA Investing LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock worth $517,291,000 after buying an additional 814,713 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after acquiring an additional 810,144 shares during the last quarter. Finally, Amundi grew its stake in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after acquiring an additional 487,489 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.